The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte‘s immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, as a treatment for locally advanced or metastatic triple-negative breast cancer (TNBC). The trial (NCT04445844) is currently recruiting patients at the Rutgers Cancer Institute of New Jersey, and is planning to also enroll participants at The Ohio State University Comprehensive Cancer Center. Additional information is available here. “The…
You must be logged in to read/download the full post.
The post First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo appeared first on BioNewsFeeds.